重组人生长激素临床应用的安全性思考

潘慧; 杜红伟

doi:10.7499/j.issn.1008-8830.2310001

PDF(531 KB)

HTML

中国当代儿科杂志 ›› 2024, Vol. 26 ›› Issue (5) : 444-449. DOI: 10.7499/j.issn.1008-8830.2310001

系列讲座——儿童矮身材的规范诊疗

重组人生长激素临床应用的安全性思考

潘慧¹, 杜红伟²

作者信息 +

Safety considerations for the clinical application of recombinant human growth hormone

PAN Hui, DU Hong-Wei

Author information +

文章历史 +

摘要

重组人生长激素（recombinant human growth hormone, rhGH）是改善身材矮小的有效治疗药物，目前rhGH可应用于包含生长激素缺乏症在内的多种原因导致的身材矮小，临床应用的扩展使其安全性问题备受关注。基于现有证据，当rhGH规范应用于生理性替代治疗时，其安全性较好。临床中，应用rhGH进行治疗期间可结合文献证据和临床经验重点关注短期安全性，长期安全性由于rhGH治疗时间不足尚无准确定论。该文梳理了在rhGH治疗过程中有可能出现的不良事件及其风险控制措施，旨在帮助临床医生了解rhGH治疗的整体安全性，改善临床规范化应用。

Abstract

Recombinant human growth hormone (rhGH) is an effective therapeutic drug for improving short stature. Currently, rhGH can be used for various causes of short stature, including growth hormone deficiency, and the expansion of its clinical application has raised concerns about its safety. Based on existing evidence, when rhGH is used in a standardized manner for physiological replacement therapy, its safety profile is favorable. In clinical practice, attention should be focused on short-term safety during rhGH treatment, with the combination of literature evidence and clinical experience. There is still no definitive conclusion on the long-term safety due to insufficient duration of rhGH treatment. This paper reviews the possible adverse events that may occur during rhGH treatment and their risk control measures, aiming to help clinical physicians understand the overall safety of rhGH treatment and improve its clinical standardization.

导出引用

潘慧, 杜红伟. 重组人生长激素临床应用的安全性思考[J]. 中国当代儿科杂志. 2024, 26(5): 444-449 https://doi.org/10.7499/j.issn.1008-8830.2310001

PAN Hui, DU Hong-Wei. Safety considerations for the clinical application of recombinant human growth hormone[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(5): 444-449 https://doi.org/10.7499/j.issn.1008-8830.2310001

参考文献

1 Tidblad A. The history, physiology and treatment safety of growth hormone[J]. Acta Paediatr, 2022, 111(2): 215-224. PMID: 34028879. DOI: 10.1111/apa.15948.
2 中华医学会儿科学分会内分泌遗传代谢学组, 《中华儿科杂志》编辑委员会, 梁雁. 基因重组人生长激素儿科临床规范应用的建议[J]. 中华儿科杂志, 2013, 51(6): 426-432. DOI: 10.3760/cma.j.issn.0578-1310.2013.06.007.
3 中华医学会儿科学分会内分泌遗传代谢学组, 中华医学会儿科学分会儿童保健学组, 中华儿科杂志编辑委员会. 儿童体格发育评估与管理临床实践专家共识[J]. 中华儿科杂志, 2021, 59(3): 169-174. PMID: 33657689. DOI: 10.3760/cma.j.cn112140-20210116-00050.
4 Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency[J]. Horm Res Paediatr, 2016, 86(6): 361-397. PMID: 27884013. DOI: 10.1159/000452150.
5 Yuen KCJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care[J]. Endocr Pract, 2019, 25(11): 1191-1232. PMID: 31760824. DOI: 10.4158/GL-2019-0405.
6 中华医学会儿科学分会内分泌遗传代谢学组, 中华儿科杂志编辑委员会. 过渡期生长激素缺乏症诊断及治疗专家共识[J]. 中华儿科杂志, 2020, 58(6): 455-460. PMID: 32521956. DOI: 10.3760/cma.j.cn112140-20200314-00237.
7 中华医学会内分泌学分会. 成人生长激素缺乏症诊治专家共识（2020版）[J]. 中华内分泌代谢杂志, 2020, 36(12): 995-1002. DOI: 10.3760/cma.j.cn311282-20201130-00798.
8 Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children[J]. J Clin Endocrinol Metab, 2010, 95(1): 167-177. PMID: 19906787. DOI: 10.1210/jc.2009-0178.
9 Mehta S, Oza V, Potashner R, et al. Allergic and non-allergic skin reactions associated with growth hormone therapy: elucidation of causative agents[J]. J Pediatr Endocrinol Metab, 2018, 31(1): 5-11. PMID: 29197220. DOI: 10.1515/jpem-2017-0309.
10 方圣博, 张晓荧, 张欣, 等. 聚乙二醇重组人生长激素致儿童过敏性休克1例[J]. 药物流行病学杂志, 2017, 26(3): 219-220. DOI: 10.19960/j.cnki.issn1005-0698.2017.03.014.
11 Mann J, Caruana D, Luo E, et al. Attenuation of human growth hormone-induced rash with graded dose challenge[J]. Cureus, 2022, 14(8): e27920. PMID: 36110455. PMCID: PMC9464419. DOI: 10.7759/cureus.27920.
12 Bamba V, Kanakatti Shankar R. Approach to the patient: safety of growth hormone replacement in children and adolescents[J]. J Clin Endocrinol Metab, 2022, 107(3): 847-861. PMID: 34636896. DOI: 10.1210/clinem/dgab746.
13 Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database [J]. Horm Res, 2007, 68(Suppl 5): 41-47. PMID: 18174706. DOI: 10.1159/000110474.
14 向蓝, 赵志鸿, 向斌. 特发性颅内压增高的认识及进展[J]. 中国医师杂志, 2023, 25(1): 157-160. DOI: 10.3760/cma.j.cn431274-20220523-00490.
15 Child CJ, Zimmermann AG, Chrousos GP, et al. Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program[J]. J Clin Endocrinol Metab, 2019, 104(2): 379-389. PMID: 30219920. PMCID: PMC6300411. DOI: 10.1210/jc.2018-01189.
16 Iughetti L, Vivi G, Balsamo A, et al. Thyroid function in patients with Prader-Willi syndrome: an Italian multicenter study of 339 patients[J]. J Pediatr Endocrinol Metab, 2019, 32(2): 159-165. PMID: 30703060. DOI: 10.1515/jpem-2018-0388.
17 S?vendahl L, Polak M, Backeljauw P, et al. Long-term safety of growth hormone treatment in childhood: two large observational studies: NordiNet IOS and ANSWER[J]. J Clin Endocrinol Metab, 2021, 106(6): 1728-1741. PMID: 33571362. PMCID: PMC8118578. DOI: 10.1210/clinem/dgab080.
18 Mostoufi-Moab S, Isaacoff EJ, Spiegel D, et al. Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy[J]. Pediatr Blood Cancer, 2013, 60(11): 1766-1771. PMID: 23818448. PMCID: PMC4564250. DOI: 10.1002/pbc.24667.
19 Witbreuk M, van Kemenade FJ, van der Sluijs JA, et al. Slipped capital femoral epiphysis and its association with endocrine, metabolic and chronic diseases: a systematic review of the literature[J]. J Child Orthop, 2013, 7(3): 213-223. PMID: 24432080. PMCID: PMC3672463. DOI: 10.1007/s11832-013-0493-8.
20 Sharma VM. Emerging mechanisms of GH-induced lipolysis and insulin resistance[J]. Pediatr Endocrinol Rev, 2019, 17(1): 4-16. PMID: 31599132. DOI: 10.17458/per.vol17.2019.s.ghlipolysisandinsulinresistance.
21 Witkowska-Sedek E, Labochka D, Stelmaszczyk-Emmel A, et al. Evaluation of glucose metabolism in children with growth hormone deficiency during long-term growth hormone treatment[J]. J Physiol Pharmacol, 2018, 69(2): 219-230. PMID: 29980142. DOI: 10.26402/jpp.2018.2.08.
22 Pellegrin MC, Michelon D, Faleschini E, et al. Glucose metabolism evaluated by glycated hemoglobin and insulin sensitivity indices in children treated with recombinant human growth hormone[J]. J Clin Res Pediatr Endocrinol, 2019, 11(4): 350-357. PMID: 30819016. PMCID: PMC6878334. DOI: 10.4274/jcrpe.galenos.2019.2019.0281.
23 U.S. Food and Drug Administration. SKYTROFA? prescribing information[EB/OL]. [2022-02-01]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761177s001lbl.pdf.
24 Maghnie M, Ranke MB, Geffner ME, et al. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort[J]. J Clin Endocrinol Metab, 2022, 107(12): 3287-3301. PMID: 36102184. PMCID: PMC9693805. DOI: 10.1210/clinem/dgac517.
25 中华人民共和国国家卫生健康委员会疾病预防控制局. 《儿童青少年脊柱弯曲异常防控技术指南》及编写说明[EB/OL]. [2021-11-01]. http://www.nhc.gov.cn/jkj/s5899tg/202111/5579c1240d034ac680a7505994aa082d.shtml.
26 Ciurea AV, Saceleanu V, Mohan A, et al. Craniopharyngiomas in children - experience of consecutive 152 operated cases[J]. Acta Endocrinol (Buchar), 2020, 16(1): 103-109. PMID: 32685048. PMCID: PMC7363995. DOI: 10.4183/aeb.2020.103.
27 中华人民共和国国家卫生健康委员会. 儿童颅咽管瘤诊疗规范（2021年版）[EB/OL]. [2021-08-30].http://www.nhc.gov.cn/yzygj/s7659/202105/3c18fec8a37d452b82fe93e2bcf3ec1e/files/3336be65bb8d4237b2f52fcd1e938504.pdf.
28 Pollock NI, Cohen LE. Growth hormone deficiency and treatment in childhood cancer survivors[J]. Front Endocrinol (Lausanne), 2021, 12: 745932. PMID: 34745010. PMCID: PMC8569790. DOI: 10.3389/fendo.2021.745932.
29 Stagi S, Ferrari V, Ferrari M, et al. Inside the Noonan "universe": literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns[J]. Front Endocrinol (Lausanne), 2022, 13: 951331. PMID: 36060964. PMCID: PMC9434367. DOI: 10.3389/fendo.2022.951331.
30 S?vendahl L, Cooke R, Tidblad A, et al. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study[J]. Lancet Diabetes Endocrinol, 2020, 8(8): 683-692. PMID: 32707116. DOI: 10.1016/S2213-8587(20)30163-7.
31 Barake M, Arabi A, Nakhoul N, et al. Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis[J]. Endocrine, 2018, 59(1): 39-49. PMID: 29030774. DOI: 10.1007/s12020-017-1440-0.
32 罗小平. 身材矮小症儿童诊疗规范[M]. 北京: 人民卫生出版社, 2019: 15-20.